Empyrean Capital Partners, LP Paratek Pharmaceuticals, Inc. Transaction History

Empyrean Capital Partners, LP

  • $2.01 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 15, 2018
SELL
$12.65 - $18.85 $8.46 Million - $12.6 Million
-669,000 Closed
0 $0
Q3 2017

Nov 14, 2017
BUY
$18.9 - $28.2 $12.6 Million - $18.9 Million
669,000
669,000 $16.8 Million

Others Institutions Holding PRTK

# of Institutions
4
Shares Held
1.54M
Call Options Held
0
Put Options Held
0
View Full List

About Paratek Pharmaceuticals, Inc.

PRTK Quotes by TradingView
  • Ticker PRTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,862,500
  • Description
  • Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...
More about PRTK
Track This Portfolio

Track Empyrean Capital Partners, LP Portfolio

Follow Empyrean Capital Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Empyrean Capital Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Empyrean Capital Partners, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email